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Tranexamic acid (TXA) is a popular antiﬁbrinolytic drug that is commonly used in patients with bleeding disorder. Major
morbidities and mortalities have been reported following inadvertent intrathecal injection of TXA. In this paper, inadvertent
intrathecal injection of TXA has resulted from similarities in appearance between TXA and heavy bupivacaine 0.5% ampoules.
The patient experienced severe pain in the back and gluteal region upon injection in association with systemic hypertension and
tachycardia followed by generalized myoclonic seizures and ventricular ﬁbrillation.
1.Introduction
The use of antiﬁbrinolytic agents including tranexamic acid
(TXA), aprotinin, and aminocaproic acid is popular in car-
diac, gynecologic, and obstetric surgeries to overcome the
increased ﬁbrinolytic activity associated with these proce-
dures [1]. Major complications in anesthesia practice have
been reported from human errors like lack of vigilance,
wronglabelingorpresentationofthesyringesandampoules,
or underestimation of the double-checking concept [2]. In
thiscasereport,TXAwasinjectedintrathecallyinsteadofhy-
perbaric bupivacaine 0.5%, because both ampoules were
having the same appearance with consequent development
of myoclonic seizures and ventricular ﬁbrillation.
2.CaseDescription
Institutional reviewboardapprovalandpatient consentwere
obtained prior to reporting the case. A 54-year-old man
was scheduled for lower-limb skin grafting. The patient was
thoroughly examined and investigated and conﬁrmed to
be ASA I physical status. Spinal anesthesia was done with
the patient in the sitting position at the L4-L5 interspace,
usinga22-gaugeneedle.Theanesthesiologistnurseprepared
3mL of 0.5% hyperbaric bupivacaine for the anesthesiology
resident. Upon injection of bupivacaine, the patient started
complaining of severe pain in the back and gluteal region.
The anesthesiologist attributed this pain to intraneural
injection. No manifestations of sensory or motor block were
noted, and the patient continued in severe intractable pain
associated with elevation of the arterial blood pressure to
170/95 and pulse rate to 130. The patient received 100µgo f
fentanyl for analgesia and 2mg of midazolam for sedation
and put on oxygen face mask. Ten minutes later, the patient
developed generalized myoclonic seizures. Consequently, the
patient received propofol 200mg and succinylcholine 80mg
for tracheal intubation and was mechanically ventilated and
then transferred to the ICU. The attending anesthesiologist
suspected accidental intrathecal injection of a wrong drug
and discovered a used TXA ampoule (500mg in 5mL)
in the trash can. In the ICU, the patient became feverish
(40◦C), and 2gm IV acetaminophen was given. Three hours
later, the patient got ventricular ﬁbrillation that respond-
ed to electrical shock of 300J. Subsequent treatment includ-
ed propranolol, amiodarone, lidocaine, and mannitol in ad-
dition to continuous mechanical ventilation. Twenty-four
hours later, the patient was weaned from mechanical ventila-
tion, extubated, and fully recovered without any neurologic
sequelae.
3. Discussion
Tranexamic acid is a competitive inhibitor of plasminogen
activation and a noncompetitive inhibitor of plasmin at2 Case Reports in Anesthesiology
higher concentrations. Its use in humans is generally well
tolerated, and its complications are minimal and include
mainly gastrointestinal upsets [1]. However, neurotoxicity
andseizureshavebeenreportedinanimalstudies[3–5].Fur-
thermore, Yamaura and coworkers reported elevation of the
systemic and intracranial pressure by direct cerebral appli-
cation of TXA for treatment of ruptured intracranial aneu-
rysm in animal models [4]. However, we know little about
eﬀectofTXAincaseitisapplieddirectlytothesubarachnoid
space in humans. In 1988, Wong and colleagues [6]r e p o r t e d
accidentalintrathecalinjectionof75mgTXAinadultpatient
undergoing appendectomyoperation. The patient developed
persistentsensoryblockofbothlowerextremitiesinaddition
to fever, myoclonus, and clonic convulsions that progressed
to a generalized seizure that responded to intravenous di-
azepam,andthepatientwasfullyrecoveredwithoutanyneu-
rologic deﬁcits. In 1999, De Leede-van der Maarl and co-
workers [7] reported accidental intrathecal injection of
50mgTXAina68-year-oldman.Thepatientexperiencedre-
fractory seizure that was treated by both diazepam and sod-
ium thiopental. Furthermore, the patient complained of
paresisinallextremities thatresolvedovertime butwithper-
sistent bilateral peroneal palsy. In 2003, Yeh and colleagues
[8] reported inadvertent intrathecal injection of 500mg of
TXA. The patient developed generalized convulsions and
hypertensive response followed by refractory ventricular
ﬁbrillation that ended the life of the patient. The authors
attributed this sequelae to a massive sympathetic discharge
induced by TXA which was near to the events encountered
in our case. Whereas triggering of seizures was explained
by suppression of the inhibitory gamma-aminobutyric acid-
(GABA)-A receptors in the cerebral cortex or lowering of
cerebral blood ﬂow with consequent cerebral ischemia [9,
10]. In 2007, Garcha and colleagues [11] reported mor-
tality after accidental intrathecal injection of TXA. In 2011,
Kaabachi et al. [12] reported accidental intrathecal injection
of 80mg TXA in a 30-year-old man. The patient experienced
severe pain in the back and gluteal region and recurrent
attacks of polymyoclonus and seizures, in addition to re-
current episodes of ventricular tachycardia that subsided
spontaneously. The patient was fully recovered within 4 days
without any neurologic sequelae.
4. Conclusion
We should emphasize that all the previously mentioned case
reports have resulted from confusion between TXA and
hyperbaric bupivacaine 0.5% ampoules that were having the
same appearance. We recommend that critical drugs like the
drugs used for spinal anesthesia have unique appearance and
package so possibility of confusion is remote. At the same
time, both the anesthesiologist and nurse must check the
ampoule label precisely and stick to the double-checking
concept.
References
[1] C. Longstaﬀ, “Studies on the mechanisms of action of apro-
tinin and tranexamic acid as plasmin inhibitors and antiﬁbri-
nolytic agents,” Blood Coagulation and Fibrinolysis, vol. 5, no.
4, pp. 537–542, 1994.
[ 2 ]J .B .C o o p e r ,R .S .N e w b o w e r ,a n dR .J .K i t z ,“ A na n a l y s i s
of major errors and equipment failures in anesthesia man-
agement: considerations for prevention and detection,” Anes-
thesiology, vol. 60, no. 1, pp. 34–42, 1984.
[3] M. G. Schlag, R. Hopf, H. Redl et al., “Convulsive seizures
following subdural application of ﬁbrin sealant containing
tranexamic acid in a rat model,” Neurosurgery,v o l .4 7 ,n o .6 ,
pp. 1463–1467, 2000.
[4] A.Yamaura,T.Nakamura,H.Makino,andY.Hagihara,“Cere-
bral complication of antiﬁbrinolytic therapy in the treatment
of ruptured intracranial aneurysm. Animal experiment and a
review of literature,” European Neurology, vol. 19, no. 2, pp.
77–84, 1980.
[5] A.Pellegrini,D.Giaretta,andR.Chemello,“Felinegeneralized
epilepsy induced by tranexamic acid (AMCA),” Epilepsia, vol.
23, no. 1, pp. 35–45, 1982.
[6] J. O. Wong, S. F. Yang, and M. H. Tsai, “Accidental injection of
tranexamic acid (Transamin) during spinal anesthesia,” Acta
Anaesthesiologica Sinica, vol. 26, no. 2, pp. 249–252, 1988.
[7] M. G. De Leede-van der Maarl, P. Hilkens, and F. Bosch, “The
epileptogenic eﬀect of tranexamic acid,” Journal of Neurology,
vol. 246, no. 9, p. 843, 1999.
[8] H. M. Yeh, H. P. Lau, P. L. Lin, W. Z. Sun, and M. S.
Mok, “Convulsionsand refractoryventricular ﬁbrillationafter
intrathecal injection of a massive dose of tranexamic acid,”
Anesthesiology, vol. 98, no. 1, pp. 270–272, 2003.
[9] R. Furtmuller, M. G. Schlag, M. Berger et al., “Tranexamic
acid, a widely used antiﬁbrinolytic agent, causes convulsions
by a gamma-aminobutyric acid(A) receptor antagonistic ef-
fect,” Journal of Pharmacology and Experimental Therapeutics,
vol. 301, pp. 168–173, 2002.
[10] S. A. Tsementzis, C. H. A. Meyer, and E. R. Hitchcock, “Cere-
bral blood ﬂow in patients with a subarachnoid haemorrhage
during treatment with tranexamic acid,” Neurochirurgia, vol.
35, no. 3, pp. 74–78, 1992.
[11] P. S. Garcha, C. V. R. Mohan, and R. M. Sharma, “Death after
an inadvertent intrathecal injection of tranexamic acid,” An-
esthesia and Analgesia, vol. 104, no. 1, pp. 241–242, 2007.
[12] O. Kaabachi, M. Eddhif, K. Rais, and M. A. Zaabar, “Inadver-
tent intrathecal injection of tranexamic acid,” Saudi Journal of
Anaesthesia, vol. 5, pp. 90–92, 2011.